Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia 1Bronchiolitis Obliterans Syndrome 1Blast Crisis 1

Interventions

nilotinib 4Cytarabine 3Filgrastim 2Cyclophosphamide 2Aprepitant 2Antilymphocyte Serum 2rasburicase 1liposomal amphotericin B 1fludarabine phosphate 1fludarabine 1bosutinib 1blinatumomab 1aldesleukin 1Water 1Voriconazole 1Urate Oxidase 1Tobacco Use Cessation Devices 1Thiotepa 1Rituximab 1Radiotherapy 1Psychiatric Rehabilitation 1Prilocaine 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Pentostatin 1Palonosetron 1Oxygen 1Interleukin-2 1Inotuzumab Ozogamicin 1Histamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia × bosutinib × Clear all
NCT02228382 2021-12-30

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Pfizer

Phase 4 Terminated
163 enrolled 27 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡